Selank

GABAergic Modulation Without Benzodiazepine Baggage#

Selank is not a GABA_A agonist — it doesn't dock into the benzodiazepine site and flood chloride channels. Instead, it acts upstream, altering the expression of GABA_A receptor subunits and the enzymes that synthesize and transport GABA itself. In rat frontal cortex, a single 300 µg/kg dose shifts transcription of Gabra1, Gabrb2, and GABA-metabolism genes like Gad1 and Gat1. The practical consequence: anxiolysis comparable to medazepam, but without sedation, tolerance, dependence, or a withdrawal syndrome on cessation.

"Selank increased expression of the Gabra1 and Gabrb2 genes, which encode subunits of the major GABA(A) receptor, and influenced the expression of genes involved in GABA synthesis and transport in the frontal cortex." — Volkova A. et al. Frontiers in Pharmacology, 2016

"Selank's anxiolytic activity is mediated by upregulation of GABAergic receptors and modulation of genes encoding enzymes responsible for GABA metabolism." — Vyunova T.V. et al. Protein and Peptide Letters, 2018

This is why Selank stacks cleanly with pre-workout caffeine, heavy training, or a stimulant nootropic — it quiets the anxiety floor without dulling drive or reaction time.

Enkephalinase Inhibition and Endogenous Opioid Tone#

The second major mechanism is inhibition of plasma enkephalin-degrading enzymes. By slowing the breakdown of endogenous leu-enkephalin, Selank raises circulating enkephalin tone — which matters because patients with generalized anxiety disorder show elevated enkephalinase activity at baseline. Selank essentially corrects a biochemical feature of the anxious state rather than masking it.

"Selank at 10–50 μM produced dose-dependent inhibition of plasma enkephalin-degrading enzymes activity, which may underlie its demonstrated anxiolytic effect." — Zozulya A.A. et al. Bulletin of Experimental Biology and Medicine, 2001

For users, this is the mechanism behind Selank's "tonic" feel — a stable mood floor that holds for hours after the peptide itself has cleared plasma, rather than a sharp on/off curve. It's also likely why rodent models show Selank attenuating aversive signs of opioid withdrawal: the enkephalin system is doing work in the background.

BDNF and Serotonergic Turnover#

Selank upregulates BDNF mRNA and protein in the hippocampus and increases serotonin turnover in the brainstem and hypothalamus — effects that persist even under pharmacological 5-HT depletion, suggesting the peptide modulates serotonergic signalling through mechanisms not dependent on current 5-HT synthesis. This is the "nootropic" half of its profile: the sustained mood lift and subtle cognitive sharpening users report over a 2–4 week block, as opposed to the acute anxiolysis of a single dose. The effect outlasts the 8–15 minute plasma half-life because downstream BDNF and receptor-expression changes persist long after the peptide is cleared.

Immunomodulatory and Cytokine Effects#

As a synthetic analog of the endogenous tetrapeptide tuftsin (with a Pro-Gly-Pro C-terminal extension for peptidase resistance), Selank inherits tuftsin's immunomodulatory activity. It shifts Th1/Th2 cytokine balance and normalizes IL-6 expression in anxiety-asthenic patients. Practically, this is the mechanism behind the "anti-asthenic" tonic effect — the reason users running it during contest prep or a heavy blast report less of the run-down, inflamed, sleep-deprived feeling that usually accompanies high cortisol loads.

Clean Clinical Profile as a Consequence of the Mechanism#

Because Selank works through receptor expression, enkephalin preservation, and BDNF upregulation rather than direct receptor agonism, it doesn't produce the downregulation, tolerance, or dependence that defines benzodiazepines. This is reflected in the clinical data.

"Selank was found to produce a pronounced anxiolytic effect similar to that of medazepam while not inducing sedation, drug dependence, or withdrawal symptoms in GAD and neurasthenia patients." — Zozulya A.A. et al. Zh Nevrol Psikhiatr Im S.S. Korsakova, 2008

"No clinically significant side effects or negative reactions were registered in patients during Selank treatment; the preparation was well tolerated and produced a stable decrease in anxiety scores." — Medvedev V.E. et al. Zh Nevrol Psikhiatr Im S.S. Korsakova, 2015

The net phenotype: anxiolysis without sedation, mood and cognitive support without stimulant jitter, and no HPTA, estrogen, prolactin, or cortisol-axis interference — which is why it drops cleanly into an AAS blast, a hair stack, or a nootropic protocol without adding a single monitoring requirement of its own.

Common (most users)#

• Mild nasal irritation or burning — the most common complaint, usually from benzyl alcohol preservative, under-diluted reconstitution, or low-pH saline. Rotate nostrils each dose, reconstitute with bacteriostatic water rather than plain sterile water, and keep sprays to 1–2 per nostril per administration.
• Transient metallic or bitter taste — post-nasal drip carrying peptide to the back of the throat. Sniff gently rather than inhaling sharply; dose upright and hold the head level for 30 seconds after spraying.
• Mild headache in the first 2–3 days — typically resolves as you settle in. Drop to 250–500 mcg/day for a few days and titrate back up.
• Blunted or "flat" affect at higher doses — a tell-tale sign you're dosing above your personal sweet spot. Selank's dose-response flattens early; back off to 500–900 mcg/day rather than pushing.
• Mild alerting effect if dosed late — not true stimulation, but enough to disrupt sleep onset in sensitive users. Keep the last dose before early afternoon.

Uncommon (dose-dependent or individual)#

• Paradoxical anxiety or irritability on first exposure — a minority of users report this in the first 2–3 days. Usually self-resolves; if it persists past day 4, stop and reassess rather than pushing through.
• Transient fatigue or low motivation at supraphysiologic doses — the overshoot presentation. If you feel duller rather than calmer, you're above your dose, not below it.
• Mild rhinorrhea or nasal congestion with daily use over several weeks. Take a 3–5 day washout; consider switching to N-Acetyl Selank (amidate), which tends to be better tolerated intranasally.
• Inadequate response during acute panic — Selank is tonic, not rescue. It does not produce benzo-like acute knockdown of a panic attack. If that's what you need, Selank is the wrong tool.

"No clinically significant side effects or negative reactions were registered in patients during Selank treatment; the preparation was well tolerated and produced a stable decrease in anxiety scores." — Medvedev et al., Zh Nevrol Psikhiatr Im S.S. Korsakova (2015)

Rare but serious#

• Hypersensitivity reaction to the peptide or preservative — itching, rash, swelling, or breathing difficulty after dosing. Stop immediately and do not rechallenge.
• Local nasal mucosal injury from chronic high-dose use with poorly-buffered product — persistent burning, crusting, or bleeding warrants stopping and letting the mucosa recover for 1–2 weeks.
• No cases of dependence, withdrawal, tolerance, HPTA suppression, liver toxicity, or cardiovascular events have been reported in the published clinical literature (Zozulya et al., 2008).

Hard contraindications#

• Pregnancy and lactation — no safety data. Do not use.
• Known peptide hypersensitivity — prior reaction to Selank, Semax, or related heptapeptides. Do not rechallenge.
• Concurrent benzodiazepine use — mechanism overlap on the GABAergic axis means additive CNS depression is plausible; not worth the stack. If you're tapering a benzo, that's a medical taper, not a Selank substitution.
• Concurrent opioid use — Selank inhibits enkephalin-degrading enzymes and modulates endogenous opioid tone. Stacking with exogenous opioids is mechanistically risky and offers no upside.

Gender-specific and PCT considerations#

Selank is non-hormonal. It does not affect the HPTA, estrogen, prolactin, or androgen axes, and dosing is identical for men and women — no virilization risk, no menstrual disruption, no PCT requirements. It does not interfere with AAS cycles, SARMs, GH, or peptide stacks, which is why physique-focused users reach for it specifically during blast phases and contest prep when cortisol and mood are under pressure. Women tolerate it at the same 500–900 mcg/day range as men. Pregnancy and lactation remain the only firm gender-linked contraindications, and purely on the absence of safety data rather than any known teratogenic signal.